INPLASY PROTOCOL

Corresponding author:
Changfu Shao

2694194988@qq.com

Author Affiliation:
jose

Support: Changfu Shao.

Review Stage at time of this submission: The review has not yet started.

Conflicts of interest:
None declared.

The comparison of percutaneous ethanol and polidocanol sclerotherapy for Cystic Kidney Disease: a systematic review and meta-analysis

Shao, C[1].

Review question / Objective: To compare the difference and efficacy between ethanol and polidocanol in treatment of Cystic Kidney Disease.
Condition being studied: The sclerotherapy agent for Cystic Kidney Disease is controversial.
Information sources: Pubmed, embase, cochrane library, CNKI, wanfang data.

INPLASY registration number: This protocol was registered with the International Platform of Registered Systematic Review and Meta-Analysis Protocols (INPLASY) on 16 February 2022 and was last updated on 16 February 2022 (registration number INPLASY202220064).

INTRODUCTION

Review question / Objective: To compare the difference and efficacy between ethanol and polidocanol in treatment of Cystic Kidney Disease.

Condition being studied: The sclerotherapy agent for Cystic Kidney Disease is controversial.

METHODS

Participant or population: Patients with Cystic Kidney Disease.

Intervention: Polidocanol sclerotherapy.

Comparator: Ethanol sclerotherapy.

Study designs to be included: Chinese and english study.

Eligibility criteria: No recurrence, reduced size of cysts.

Information sources: pubmed, embase, cochrane library, CNKI, wanfang data.

Main outcome(s): No recurrence, reduced size of cysts.

Quality assessment / Risk of bias analysis: Cochrane List.

Strategy of data synthesis: Stata or review manager.

Subgroup analysis: Country, race, dose, size of renal cyst and so on.

Sensitivity analysis: Funnel plot, Subgroup analysis.

Language: Chinese and english.

Country(ies) involved: China.

Keywords: Kidney Diseases, Cystic Punctures drainage Sclerotherapy.

Contributions of each author:
Author 1 - Changfu Shao.
Email: 2694194988@qq.com